| Followers | 21 |
| Posts | 2227 |
| Boards Moderated | 0 |
| Alias Born | 06/08/2009 |
Thursday, November 05, 2009 6:48:02 AM
Hi Ed, It's an unknown - and markets just love unknowns. 
It's a great "honor" to have a drug on the list but when Global Gains pushed them on this it was clear there was some pricing pressure.
I'm going to listen to some of the upcoming CC's to see if they give a clue.
"so I'm guessing the Chinese government isn't restricting the prices too tightly, although correct me if that's wrong?"
That would be my best guess. They seem to understand businesses have to make money.
They also want more innovation - so drugs which are developed/ unique should get higher margins.
I think the big change is that you no longer have to go through Doctors/hospitals to get all your drugs (read an article put on the CXYN or this board about that)... and I assume that more people can buy through pharmacies... so CXYN share holders have reason to be optomistic about volumes going forward. I wonder if peoples see this the same was as I do?
rich
It's a great "honor" to have a drug on the list but when Global Gains pushed them on this it was clear there was some pricing pressure. I'm going to listen to some of the upcoming CC's to see if they give a clue.
"so I'm guessing the Chinese government isn't restricting the prices too tightly, although correct me if that's wrong?"
That would be my best guess. They seem to understand businesses have to make money.
They also want more innovation - so drugs which are developed/ unique should get higher margins.
I think the big change is that you no longer have to go through Doctors/hospitals to get all your drugs (read an article put on the CXYN or this board about that)... and I assume that more people can buy through pharmacies... so CXYN share holders have reason to be optomistic about volumes going forward. I wonder if peoples see this the same was as I do?
rich
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
